Rallis Chris A's Form 4 filing
Fennec Pharmaceuticals Inc. (FENC) · filed May 12, 2026
- Accession no.
- 0001185945-26-000002
- Filed
- May 12, 2026
- Trade date
- May 11, 2026
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $58.8K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Rallis Chris ACIK 0001185945 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 11, 2026 | Common Shares | MOption exerciseAcquired | +14,344 | $2.44 | +$34,999.36 | 71,423 | Direct | |
| May 11, 2026 | Common Shares | SSaleDisposed | −8,346 | $7.04 | −$58,755.84 | 63,077 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 11, 2026 | Common shares | MOption exerciseDisposed | −14,344 | $2.44 | −$34,999.36 | 186,189 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.